Type 2 diabetes drugs #

The next-generation T2D race, ranked by HbA1c reduction: incretins, once-weekly basal insulins, and SGLT2 cardio-renal leaders across Eli Lilly, Novo Nordisk, Sanofi, Boehringer Ingelheim, and AstraZeneca.

As of 2026-06-22. Updated as catalysts move. · Tracking the weight-loss SKUs of these molecules? See the obesity drug race.

33 days

Next thesis-moving catalyst Novo Nordisk: Q2 2026 earnings Aug 5, 2026

approved drugs tracked

in Phase 3 (incl. filed)

-2.46%

deepest HbA1c reduction
(Tirzepatide, SURPASS-2)

$18.1B

tracked T2D SKU revenue
(Q1 2026)

Compare drugs

HbA1c-over-time trajectories, efficacy vs tolerability, and a sortable data table - one filter across every next-gen T2D drug.

Open the explorer →

Pipeline

Every disclosed T2D asset by sponsor and phase, plus the M&A and partnerships that built the field.

See the pipeline →

Sales

Quarterly revenue per T2D SKU in USD, 2019-2026 - Mounjaro overtaking Ozempic as the older classes erode.

View sales →

Calendar

Forward catalysts - earnings, trial readouts, and FDA decisions - ordered by date and tiered by stock impact.

See the calendar →

Latest blog: Not Apples to Apples: How Shifting Trial Criteria Distort GLP-1 Weight-Loss Headlines (2026-05-15) · more posts tagged diabetes